Abstract | BACKGROUND: PATIENTS AND METHODS: One hundred and two patients with advanced esophageal cancer were treated with paclitaxel 80 mg/m2 weekly over a 1-h infusion. One cycle was defined as 4 weeks of therapy. Ninety-five patients were assessable for toxicity and 86 patients who completed at least two cycles of treatment were assessable for response. Sixty-six patients had adenocarcinoma (66%) and 65 patients (68%) had no prior chemotherapy. RESULTS: A median of three cycles was delivered (range 1-11). Partial responses (PRs) were seen in 11 patients [13%, 95% confidence interval (CI) 6% to 20%]. In patients without prior chemotherapy, PRs were seen in 10 patients (15%, 95% CI 6% to 24%), with comparable response in adenocarcinoma (8/50, 16%) and squamous carcinoma (2/15, 13%). Limited response was seen in patients with prior chemotherapy (1/21, 5%). The median duration of response was 172 days. The median survival was 274 days. Therapy was well tolerated with minimal hematologic or grade 3 or 4 toxicity. CONCLUSION:
|
Authors | D H Ilson, R G Wadleigh, L P Leichman, D P Kelsen |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 18
Issue 5
Pg. 898-902
(May 2007)
ISSN: 0923-7534 [Print] England |
PMID | 17351256
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- Adenocarcinoma
(drug therapy, pathology)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Arthralgia
(chemically induced)
- Carcinoma, Squamous Cell
(drug therapy, pathology)
- Drug Administration Schedule
- Esophageal Neoplasms
(drug therapy, pathology)
- Female
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neutropenia
(chemically induced)
- Paclitaxel
(administration & dosage, adverse effects)
- Survival Analysis
- Thrombocytopenia
(chemically induced)
- Time Factors
- Treatment Outcome
|